RU2327695C2 - Ингибиторы фактора ингибирования миграции макрофага и способы для их идентификации - Google Patents
Ингибиторы фактора ингибирования миграции макрофага и способы для их идентификации Download PDFInfo
- Publication number
- RU2327695C2 RU2327695C2 RU2003132534/04A RU2003132534A RU2327695C2 RU 2327695 C2 RU2327695 C2 RU 2327695C2 RU 2003132534/04 A RU2003132534/04 A RU 2003132534/04A RU 2003132534 A RU2003132534 A RU 2003132534A RU 2327695 C2 RU2327695 C2 RU 2327695C2
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- group
- halogen
- substituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 60
- 230000005764 inhibitory process Effects 0.000 title claims abstract 3
- 239000003112 inhibitor Substances 0.000 title claims 8
- 238000013508 migration Methods 0.000 title abstract 2
- 230000005012 migration Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 178
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 21
- 239000001301 oxygen Substances 0.000 claims abstract 21
- 150000003839 salts Chemical class 0.000 claims abstract 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 11
- 230000000694 effects Effects 0.000 claims abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 6
- 206010040070 Septic Shock Diseases 0.000 claims abstract 3
- 230000036303 septic shock Effects 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 125000005843 halogen group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 16
- 229910052717 sulfur Chemical group 0.000 claims 15
- 238000004519 manufacturing process Methods 0.000 claims 13
- 241001465754 Metazoa Species 0.000 claims 12
- 125000002541 furyl group Chemical group 0.000 claims 11
- 125000001544 thienyl group Chemical group 0.000 claims 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- -1 —C (═O) —CH 2 Br Chemical group 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- GCCKHXWBNPBUOD-UHFFFAOYSA-N CC(c1c[o]cc1)=O Chemical compound CC(c1c[o]cc1)=O GCCKHXWBNPBUOD-UHFFFAOYSA-N 0.000 description 2
- NTWPHRRJKOZVIB-UHFFFAOYSA-N CCOC(C(C(N(C)c1ccc(C)cc11)=O)=C1N(CC1)CCN1C(c1ccc[o]1)=O)=O Chemical compound CCOC(C(C(N(C)c1ccc(C)cc11)=O)=C1N(CC1)CCN1C(c1ccc[o]1)=O)=O NTWPHRRJKOZVIB-UHFFFAOYSA-N 0.000 description 1
- CATZSEQOGCUPDJ-UHFFFAOYSA-N CCOC(C(C(N(CCCN(C)C)c(c1c2)ccc2Cl)=O)=C1N(CC1)CCN1C(c1ccc[s]1)=O)=O Chemical compound CCOC(C(C(N(CCCN(C)C)c(c1c2)ccc2Cl)=O)=C1N(CC1)CCN1C(c1ccc[s]1)=O)=O CATZSEQOGCUPDJ-UHFFFAOYSA-N 0.000 description 1
- OIGIAFYTXBREHH-UHFFFAOYSA-N CCOC(C(C(N(Cc1ccccc1)c1c2cc(C)cc1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O)=O Chemical compound CCOC(C(C(N(Cc1ccccc1)c1c2cc(C)cc1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O)=O OIGIAFYTXBREHH-UHFFFAOYSA-N 0.000 description 1
- KTFCVAZGXKEUSN-UHFFFAOYSA-N CCOC(C(C(Nc1ccccc11)=O)=C1Cl)=O Chemical compound CCOC(C(C(Nc1ccccc11)=O)=C1Cl)=O KTFCVAZGXKEUSN-UHFFFAOYSA-N 0.000 description 1
- 0 CCOC(C(C(Nc1ccccc11)=O)=C1N(CC1)CCN1C(*)=O)=O Chemical compound CCOC(C(C(Nc1ccccc11)=O)=C1N(CC1)CCN1C(*)=O)=O 0.000 description 1
- OLPFASAWVHXIKA-UHFFFAOYSA-N CCOC(c(c(OCCCN(C)C)nc1c2cc(C)cc1)c2N(CC1)CCN1C(c(cc1)ccc1Cl)=O)=O Chemical compound CCOC(c(c(OCCCN(C)C)nc1c2cc(C)cc1)c2N(CC1)CCN1C(c(cc1)ccc1Cl)=O)=O OLPFASAWVHXIKA-UHFFFAOYSA-N 0.000 description 1
- CPGXWHHVRBWAEE-UHFFFAOYSA-N CCOC(c(c(OCCCN(C)C)nc1c2cccc1)c2N(CC1)CCN1C(c1ccc[o]1)=O)=O Chemical compound CCOC(c(c(OCCCN(C)C)nc1c2cccc1)c2N(CC1)CCN1C(c1ccc[o]1)=O)=O CPGXWHHVRBWAEE-UHFFFAOYSA-N 0.000 description 1
- MUBUQRXKIWWINH-UHFFFAOYSA-N CN(C)CCCOc1nc2ccccc2c(N(CC2)CCN2C(c(cc2Cl)ccc2Cl)=O)c1[N+]([O-])=O Chemical compound CN(C)CCCOc1nc2ccccc2c(N(CC2)CCN2C(c(cc2Cl)ccc2Cl)=O)c1[N+]([O-])=O MUBUQRXKIWWINH-UHFFFAOYSA-N 0.000 description 1
- UIUCUKABOKJLOG-UHFFFAOYSA-N Cc(cc1c(N(CC2)CCN2C(c2ccc[o]2)=O)c2[N+]([O-])=O)ccc1nc2OCc1ccccc1 Chemical compound Cc(cc1c(N(CC2)CCN2C(c2ccc[o]2)=O)c2[N+]([O-])=O)ccc1nc2OCc1ccccc1 UIUCUKABOKJLOG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29364201P | 2001-05-24 | 2001-05-24 | |
| US60/293642 | 2001-05-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003132534A RU2003132534A (ru) | 2005-04-20 |
| RU2327695C2 true RU2327695C2 (ru) | 2008-06-27 |
Family
ID=23129922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003132534/04A RU2327695C2 (ru) | 2001-05-24 | 2002-05-24 | Ингибиторы фактора ингибирования миграции макрофага и способы для их идентификации |
Country Status (24)
| Country | Link |
|---|---|
| US (14) | US7105519B2 (enExample) |
| EP (1) | EP1389110B1 (enExample) |
| JP (1) | JP4346312B2 (enExample) |
| KR (1) | KR100896973B1 (enExample) |
| CN (1) | CN1523989A (enExample) |
| AR (1) | AR036032A1 (enExample) |
| AT (1) | ATE461920T1 (enExample) |
| AU (2) | AU2002303906B2 (enExample) |
| BR (1) | BR0209948A (enExample) |
| CA (1) | CA2447103A1 (enExample) |
| CZ (1) | CZ20033503A3 (enExample) |
| DE (1) | DE60235750D1 (enExample) |
| ES (1) | ES2342877T3 (enExample) |
| HU (1) | HUP0500101A3 (enExample) |
| IL (1) | IL158550A0 (enExample) |
| MX (1) | MXJL03000038A (enExample) |
| MY (1) | MY140679A (enExample) |
| NZ (1) | NZ529244A (enExample) |
| PL (1) | PL367127A1 (enExample) |
| PT (1) | PT1389110E (enExample) |
| RU (1) | RU2327695C2 (enExample) |
| UY (1) | UY27304A1 (enExample) |
| WO (1) | WO2002094203A2 (enExample) |
| ZA (1) | ZA200309738B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002255961B2 (en) | 2001-03-29 | 2007-08-23 | Baxalta GmbH | Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP2270505A1 (en) | 2002-04-26 | 2011-01-05 | Takeda Pharmaceutical Company Limited | A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF) |
| MXPA05000081A (es) | 2002-06-27 | 2005-04-11 | Schering Ag | Quinolinas sustituidas antagonistas del receptor ccr5. |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US7364869B2 (en) * | 2003-07-29 | 2008-04-29 | The J. David Gladstone Institutes | Method of detecting antigen-specific T lymphocytes |
| AU2004268941A1 (en) * | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
| AU2011265309B2 (en) * | 2003-11-21 | 2014-06-05 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
| EP1740167B1 (en) * | 2004-03-29 | 2013-08-28 | The Feinstein Institute for Medical Research | Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor |
| DE102004029573A1 (de) * | 2004-06-18 | 2005-12-29 | Gambro Lundia Ab | MIF-Adsorbent |
| AU2004323369A1 (en) * | 2004-09-17 | 2006-03-23 | Siang Beng Chng | System and method for batch conversion of RFID tag to RFID label |
| US20060229314A1 (en) * | 2005-03-24 | 2006-10-12 | Jagadish Sircar | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
| WO2007038551A2 (en) * | 2005-09-26 | 2007-04-05 | Avigen, Inc. | Use of ibudilast for treating drug and behavioral addictions |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| US8362053B2 (en) | 2006-03-24 | 2013-01-29 | The Feinstein Institute For Medical Research | Modified macrophage migration inhibitory factor inhibitors |
| CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| CA2653345A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| US20070281924A1 (en) * | 2006-05-31 | 2007-12-06 | Gaeta Federico C | MIF inhibitors for treating neuropathic pain and associated syndromes |
| US7845914B2 (en) * | 2007-02-15 | 2010-12-07 | Deere & Company | Self-priming fast fill sprayer pump system |
| US9272034B2 (en) * | 2007-10-04 | 2016-03-01 | The Regents Of The University Of California | Treatment of conditions related to shock |
| US9643922B2 (en) * | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| EP2198879A1 (en) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
| JP2013538858A (ja) | 2010-10-02 | 2013-10-17 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | 腸機能不全の最小化 |
| WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| CN104334173B (zh) | 2012-05-01 | 2017-05-03 | 特兰斯拉图姆医学公司 | 用于治疗和诊断致盲性眼病的方法 |
| WO2014200872A1 (en) | 2013-06-09 | 2014-12-18 | Rjs Biologics Llc | Pharmaceutical compounds targeted by mif affinity-tethered moieties |
| US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| AU2016297037B9 (en) * | 2015-07-17 | 2020-10-29 | Fujifilm Toyama Chemical Co., Ltd. | Nitrogen-containing heterocyclic compound |
| CN111518076B (zh) * | 2018-01-17 | 2021-06-01 | 杭州阿诺生物医药科技有限公司 | 具有吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法 |
| KR20210009315A (ko) | 2018-04-11 | 2021-01-26 | 오하이오 스테이트 이노베이션 파운데이션 | 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물 |
| WO2019197842A1 (en) | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| RS64285B1 (sr) | 2018-06-27 | 2023-07-31 | Bristol Myers Squibb Co | Jedinjenja naftiridinona korisna kao aktivatori t ćelija |
| WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| BR112022012222A2 (pt) | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Derivados de piperazina substituídos úteis como ativadores de células t |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| MX2022006958A (es) | 2019-12-23 | 2022-07-12 | Bristol Myers Squibb Co | Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t. |
| BR112022012220A2 (pt) * | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t |
| CN113121435B (zh) * | 2021-04-20 | 2022-08-30 | 辽宁大学 | 一种2,4-二氯喹啉类化合物的合成方法 |
| CN119074725A (zh) * | 2024-09-11 | 2024-12-06 | 北京大学第一医院(北京大学第一临床医学院) | 靶向mif在制备用于治疗特应性皮炎的药物中应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
| US6028081A (en) * | 1997-08-29 | 2000-02-22 | Ssp Co., Ltd. | Substituted quinolone derivatives and pharmaceuticals containing the same |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| US4299814A (en) | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
| ATE64957T1 (de) | 1984-02-22 | 1991-07-15 | Wellcome Found | Klonieren von dna fuer protozoenantigene. |
| US5869534A (en) | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US5733933A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5733524A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5801200A (en) | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5700447A (en) | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| AU592753B2 (en) | 1984-05-24 | 1990-01-25 | Ciba-Geigy Ag | Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications |
| JPH0672158B2 (ja) | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
| US4708937A (en) | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8602626D0 (en) | 1986-02-04 | 1986-03-12 | Ciba Geigy Ag | Neurite-promoting factor |
| ES2052602T3 (es) | 1986-10-03 | 1994-07-16 | Ciba Geigy Ag | Nuevos peptidos afines a las linfocinas. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH04504111A (ja) | 1989-03-17 | 1992-07-23 | ジェネティックス・インスティテュート・インコーポレイテッド | ヒトマクロファージ遊走阻止因子 |
| FI82144C (fi) | 1989-03-22 | 1991-01-10 | Wallac Oy | Foerfarande foer samtidig bestaemning av flera ligander. |
| GB8915414D0 (en) | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5328990A (en) | 1991-04-26 | 1994-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of macrophage migration inhibition factor from ocular lens |
| US5352660A (en) | 1991-10-31 | 1994-10-04 | Mount Sinai Hospital Corporation | Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system |
| US5624804A (en) | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
| US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| DE69435303D1 (de) | 1993-05-17 | 2010-09-02 | Cytokine Pharmasciences Inc | Er behandlung von krankheiten bei denen eine cytok |
| US6645493B1 (en) | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| US5650295A (en) | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| SI9400363A (en) | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
| US5955203A (en) | 1994-10-05 | 1999-09-21 | Simpson Timber Company | Resin-coated overlays for solid substrates |
| WO1996015242A2 (en) | 1994-11-16 | 1996-05-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
| DE19601697A1 (de) | 1996-01-18 | 1997-07-24 | Wacker Chemie Gmbh | Redispergierbare Tackifierpulver |
| US6420188B1 (en) | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| EP0898709A2 (en) | 1996-04-18 | 1999-03-03 | Ariad Pharmaceuticals, Inc. | $i(IN VITRO) FLUORESCENCE POLARIZATION ASSAY |
| US5883224A (en) | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| US6413939B1 (en) | 1997-10-31 | 2002-07-02 | The Picower Institute For Medical Research | Inducible phosphofructokinase and the Warburg effect |
| US6238874B1 (en) | 1998-07-28 | 2001-05-29 | Biometric Imaging, Inc. | Cell motility assay |
| JP4426724B2 (ja) * | 1998-08-07 | 2010-03-03 | イミュネックス・コーポレーション | Ｌｄｃａｍと称される分子 |
| US6214343B1 (en) | 1999-05-24 | 2001-04-10 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of necrotizing enterocolitis |
| AU1235601A (en) * | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
| CN1842346A (zh) | 2001-01-12 | 2006-10-04 | 塞托凯恩药物科学公司 | 由巨噬细胞迁移抑制因子调节细胞毒性淋巴细胞反应 |
| AU2002255961B2 (en) | 2001-03-29 | 2007-08-23 | Baxalta GmbH | Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| EP1424336A4 (en) | 2001-09-03 | 2004-11-10 | Takeda Chemical Industries Ltd | 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE |
| FR2829491B1 (fr) | 2001-09-12 | 2005-09-30 | Diverchim | Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase |
| WO2003065979A2 (en) | 2001-12-05 | 2003-08-14 | North Shore-Long Island Jewish Research Institute | Methods of diagnosis, monitoring and treatment of fertility |
| US20040019921A1 (en) | 2001-12-19 | 2004-01-29 | Fingerle-Rowson Gunter R. | Non-human mammal with disrupted or modified MIF gene, and uses thereof |
| EP2270505A1 (en) | 2002-04-26 | 2011-01-05 | Takeda Pharmaceutical Company Limited | A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF) |
| JP4828823B2 (ja) | 2002-06-07 | 2011-11-30 | コーティカル・ピーティーワイ・リミテッド | 治療用分子および方法−１ |
| CN1675154A (zh) | 2002-06-07 | 2005-09-28 | 科蒂科股份有限公司 | 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物 |
| AU2003260810A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| AU2003289176A1 (en) | 2002-12-05 | 2004-07-29 | Takeda Pharmaceutical Company Limited | 1,3-benzothiazinone derivatives, process for producing the same and use thereof |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US7361474B2 (en) | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
| AU2004268941A1 (en) | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US20060229314A1 (en) | 2005-03-24 | 2006-10-12 | Jagadish Sircar | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
-
2002
- 2002-05-23 UY UY27304A patent/UY27304A1/es not_active Application Discontinuation
- 2002-05-23 MY MYPI20021922A patent/MY140679A/en unknown
- 2002-05-24 RU RU2003132534/04A patent/RU2327695C2/ru not_active IP Right Cessation
- 2002-05-24 BR BR0209948-9A patent/BR0209948A/pt not_active Application Discontinuation
- 2002-05-24 CA CA002447103A patent/CA2447103A1/en not_active Abandoned
- 2002-05-24 IL IL15855002A patent/IL158550A0/xx unknown
- 2002-05-24 EP EP02731971A patent/EP1389110B1/en not_active Expired - Lifetime
- 2002-05-24 WO PCT/US2002/016963 patent/WO2002094203A2/en not_active Ceased
- 2002-05-24 NZ NZ529244A patent/NZ529244A/en unknown
- 2002-05-24 CZ CZ20033503A patent/CZ20033503A3/cs unknown
- 2002-05-24 PT PT02731971T patent/PT1389110E/pt unknown
- 2002-05-24 HU HU0500101A patent/HUP0500101A3/hu unknown
- 2002-05-24 AU AU2002303906A patent/AU2002303906B2/en not_active Ceased
- 2002-05-24 CN CNA02810501XA patent/CN1523989A/zh active Pending
- 2002-05-24 KR KR1020037015359A patent/KR100896973B1/ko not_active Expired - Fee Related
- 2002-05-24 AR ARP020101966A patent/AR036032A1/es unknown
- 2002-05-24 JP JP2002590924A patent/JP4346312B2/ja not_active Expired - Fee Related
- 2002-05-24 AT AT02731971T patent/ATE461920T1/de active
- 2002-05-24 DE DE60235750T patent/DE60235750D1/de not_active Expired - Lifetime
- 2002-05-24 ES ES02731971T patent/ES2342877T3/es not_active Expired - Lifetime
- 2002-05-24 US US10/156,650 patent/US7105519B2/en not_active Expired - Fee Related
- 2002-05-24 MX MXJL03000038A patent/MXJL03000038A/es active IP Right Grant
- 2002-05-24 PL PL02367127A patent/PL367127A1/xx unknown
-
2003
- 2003-12-17 ZA ZA200309738A patent/ZA200309738B/xx unknown
-
2005
- 2005-07-15 US US11/182,241 patent/US7732146B2/en not_active Expired - Fee Related
- 2005-07-15 US US11/182,360 patent/US7514225B2/en not_active Expired - Fee Related
- 2005-11-07 US US11/268,375 patent/US7084141B2/en not_active Expired - Fee Related
-
2006
- 2006-01-31 US US11/344,938 patent/US7202248B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,842 patent/US7238809B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,785 patent/US7192955B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,628 patent/US7192961B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,552 patent/US7235565B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/416,004 patent/US7157469B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,998 patent/US7129236B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/416,165 patent/US7230106B2/en not_active Expired - Fee Related
- 2006-12-07 US US11/635,319 patent/US7435737B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 US US11/687,611 patent/US7432374B2/en not_active Expired - Fee Related
- 2007-04-04 AU AU2007201493A patent/AU2007201493A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
| US6028081A (en) * | 1997-08-29 | 2000-02-22 | Ssp Co., Ltd. | Substituted quinolone derivatives and pharmaceuticals containing the same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2327695C2 (ru) | Ингибиторы фактора ингибирования миграции макрофага и способы для их идентификации | |
| DK342883A (da) | Fremgangsmaade til fremstilling af xantinderivater | |
| RU2001133004A (ru) | Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции | |
| ES2005059B3 (es) | Nuevo procedimiento de preparacion de fibratos. | |
| JP2005500266A5 (enExample) | ||
| RU2218337C2 (ru) | Производные тиазола, способ их получения и фармацевтическая композиция на их основе | |
| EA200000334A1 (ru) | Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции | |
| KR900009097A (ko) | 포유동물내 내생독소 쇼크의 치료 방법 | |
| RU97119064A (ru) | Применение альфа(il)-агонистов для лечения недержания мочи | |
| RU2007128061A (ru) | Индазол-карбоксамидные соединения | |
| US12466816B2 (en) | Fused cyclic compound capable of degrading protein and use thereof | |
| RU95115522A (ru) | Соединение, пригодные для лечения заболеваний цнс, фармацевтическая композиция | |
| JP2017530163A (ja) | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 | |
| SE7601143L (sv) | Nytt oxadiazolinonderivat | |
| KR910016738A (ko) | 질소함유고리계를 갖는 신규한 제약학적 화합물 및 조성물, 그들의 제조방법 및 그들을 사용한 트롬복산 신테타제 효소, 고혈압 및 부정맥의 억제 방법 | |
| PT73280B (de) | Neue imidazol derivate verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate | |
| SE8006365L (sv) | Cyklohexankarboxylsyraderivat | |
| JPS5923252A (ja) | チロキシンの蛍光測定もしくは比色による定量分析法 | |
| DK151965C (da) | Analogifremgangsmaade til fremstilling af piperazinsubstituerede 3-alkyltheobrominforbindelser | |
| ATE69611T1 (de) | Piperazinylalkylpiperazindion-derivate, ihre verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen. | |
| EP0173377A3 (en) | Pyrimidone compounds, their preparation and pharmaceutical compositions containing them | |
| JPWO2003033024A1 (ja) | 細胞増殖抑制剤 | |
| DE3884319D1 (de) | Imidazobenzodiazepine und ihre Säureadditionssalze, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen. | |
| JPS5888367A (ja) | フエノバルビタ−ル又はプリミドンの免疫化学的定量に用いる化合物 | |
| DK0426557T3 (da) | Fremgangsmåde til fremstilling af (1R,2R)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamid-1-oxider, mellemprodukter anvendt ved denne fremgangsmåde og fremstilling af disse mellemprodukter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130525 |